In October 2021, the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO), which evaluates vaccine applications, had recommended granting an approval for Covaxin for children aged between 2 and 18 years. However, the regulator has decided to restrict the approval to only teens, instead of the younger age group.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3eq6ncE
via IFTTT
0 comments:
Post a Comment